Published in TB and Outbreaks Week, December 30th, 2003
Hemorrhagic fever from the Ebola virus is fatal in up to 80% of cases in humans. The virus is thought to cause excessive blood coagulation and thrombosis leading to organ dysfunction. Inhibition of the blood coagulation pathway could therefore be a potential therapeutic approach for Ebola treatment.
Thomas W. Geisbert from the U.S. Army Medical Research Institute of Infectious Diseases and colleagues injected 12 rhesus macaques with the Ebola virus to induce the deadly Ebola haemorrhagic fever....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.